Family Cancer History Still a Mystery to Many Women Results from a nationwide survey conducted on the attitudes, knowledge, and practices related to risk assessment, prevention, and screening for breast and ovari... Read More
Myriad Genetics Reports Second Quarter Financial Results Highlights: Revenue of $179.3 million for the quarter ended June 30, 2022 Excluding revenue from divested businesses, revenue increased 7% year-over-year an... Read More
Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022 Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second-quarter earnings conference call on Thursday, Au... Read More
Myriad Genetics to Share Update on Business Transformation, Research and Development Pipeline, and Growth Plans at Investor Day on Aug. 11, 2022 Myriad Genetics, Inc., (NASDAQ: MYGN), will host an Investor Day on Aug. 11, 2022, providing a strategic business update and overview of the company’s growth ... Read More
Access to Myriad Genetics’ GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial Study showed PGx testing helps clinicians prescribe fewer medications with gene-drug interactions Major Depressive Disorder (MDD) remission rates were signif... Read More